In contrast to the recently developed MLL1-inhibitors for treatment of MLL-r leukemia that typically require days to reduce the viability of MLL-r cells, CCI-007 rapidly suppresses the characteristic MLL target gene signature and induces caspase-dependent apoptosis in sensitive cell lines within hours of treatment. Here, KMT2A is linked to leukemia.